ArticleStem cells international2011
Potential clinical applications for human pluripotent stem cell-derived blood components.
Article in Stem cells international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- SCL/TAL1-mediated transcriptional network enhances megakaryocytic specification of human embryonic stem cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2015Article
- Dendritic cells derived from pluripotent stem cells: Potential of large scale production.World journal of stem cells · 2014Review
- An experimental approach to the generation of human embryonic stem cells equivalents.Molecular biotechnology · 2014Review
- SON connects the splicing-regulatory network with pluripotency in human embryonic stem cells.Nature cell biology · 2013Article
- Progress and prospects in stem cell therapy.Acta pharmacologica Sinica · 2013Review
- Induced pluripotent stem cells in clinical hematology: potentials, progress, and remaining obstacles.Current opinion in hematology · 2012Review
- Tissue engineered strategies for skeletal muscle injury.Stem cells international · 2012Review
- Advances in meniscal tissue engineering.Stem cells international · 2012Review
- Stem Cell Therapy: A New Treatment for Burns?Pharmaceuticals (Basel, Switzerland) · 2011Review
- The Ongoing Challenge of Hematopoietic Stem Cell-Based Gene Therapy for β-Thalassemia.Stem cells international · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ability of human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) to divide indefinitely without losing pluripotency and to theoretically differentiate into any cell type in the body makes them highly attractive cell sources for large scale regenerative medicine purposes. The current use of adult stem cell-derived products in hematologic intervention sets an important precedent and provides a guide for developing hESC/iPSC based therapies for the blood system. In this review, we highlight biological functions of mature cells of the blood, clinical conditions requiring the transfusion or stimulation of these cells, and the potential for hESC/iPSC-derivatives to serve as functional replacements. Many researchers have already been able to differentiate hESCs and/or iPSCs into specific mature blood cell types. For example, hESC-derived red blood cells and platelets are functional in tasks such as oxygen delivery and blood clotting, respectively and may be able to serve as substitutes for their donor-derived counterparts in emergencies. hESC-derived dendritic cells are functional in antigen-presentation and may be used as off-the-shelf vaccine therapies to stimulate antigen-specific immune responses against cancer cells. However, in vitro differentiation systems used to generate these cells will need further optimization before hESC/iPSC-derived blood components can be used clinically.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.